Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macrophage therapy for liver cirrhosis
ISRCTN10368050Phase 2Completed
- Sponsor
- Accord Healthcare
- Start
- Aug 2016
- Modality
- CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
Phase 2, randomised, open-label trial of autologous macrophage therapy in Cirrhosis (3 arms), sponsored by Accord Healthcare. Primary endpoints: Safety and feasibility of reinfusion of autologous macrophages, Maximum safe dose of infusion and 1 more. Started Aug 2016; status: completed.
02
Drugs
autologous macrophage therapy
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on ISRCTN10368050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10368050.